STOCKS TELEGRAPH

Tag: SLRX

  • Salarius Pharmaceuticals Inc. (SLRX) Rebounds After Hours Following its Recent Downfall

    On March 15, Salarius Pharmaceuticals Inc. (SLRX) finally rebounded in the after-hours following its continued downfall after its latest earnings. The company had declared its 2021 financial results on March 10.

    Source: iStock

    During the regular trading session, the stock suffered a loss of 7.00% while the volume of shares exchanged remained above the average. The stock closed the session in the red at a price of $0.3441 per share. Following this, the stock rebounded in the after-hours to add a good 10.43%. Hence, SLRX stock was trading at a value of $0.3800 per share in the after-hours on Tuesday.

    The clinical-stage oncology company, Salarius Pharmaceuticals Inc. is based in Houston, TX. Currently, its 45.21 million outstanding shares trade at a market capitalization of $16.73 million.

    What Happened with SLRX?

    On March 10, the company reported its financial results for the fourth quarter and full-year 2021. Following this, the stock entered a downtrend which continued till March 15’s regular session. After plunging down for over 10.39% in the past five days, the stock finally rebounded and entered green in the after-hours on Tuesday. Since there is no recent news from the company, the downfall seems to be the reason for the comeback. In addition to external factors, it seems the low price was taken as a good buying opportunity by the investors.

    Presently, SLRX stock stands at a year-to-date loss of 30.57% while it subtracted a huge value of 77.06% in the past year.

    2021 Financial Results

    For Q4 2021, the company reported a net loss of 44.1 million against $1.8 million in the year-ago period. Therefore, the net loss per basic and diluted share was $0.09 and $0.10 in Q4 2021 and 2020, respectively.

    Moreover, the fiscal 2021 net loss was $12.8 million against $7.4 million for fiscal 2020. Thus, the net loss per basic and diluted share was $0.31 and $0.50 for fiscal 2021 and 2020, respectively.

    Furthermore, SLRX ended 2021 with cash, cash equivalents, and restricted cash of $29.2 million. This compares to $11.1 million at the end of fiscal 2020. The company expects the cash position to be enough to fund its operations through 2023.

    SLRX’s Recent Participations

    Recently, the company participated in the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference. SLRX’s CEO David Arthur, presented at the conference on February 24, 2022.

    Previously, Mr. Arthur also presented at the 2022 BIO CEO & Investor Conference which took place from February 14-17, 2022.

  • Salarius Pharmaceuticals, Inc. (SLRX) Stock Rebounds Aftermarket, Here’s What’s Happening.

    Salarius Pharmaceuticals, Inc. (SLRX) Stock Rebounds Aftermarket, Here’s What’s Happening.

    Salarius Pharmaceuticals, Inc. (SLRX) is a leading late-stage biotherapeutics firm engaged in developing cancer therapeutics for oncology patients. The lead pipeline candidate of the company is Seclidemstat in Phase 1/2 clinical-stage used for treating prostate, breast, ovary cancer, and tumors.

    The price of SLRX stock during the regular trading of March 9, 2022, was $0.37 with a decline of 2.40%. At the last check of the aftermarket, the stock rebounded by 13.3%.

    SLRX: Events and Happenings

    On March 03, 2022, SLRX updated that it will release its financials for the three months ended December 31, 2021, on March 10, 2022. The company will also host a conference call and webcast to discuss its corporate matters. On February 17, 2022, SLRX reported its Executive management’s participation at the Virtual Diamond Equity Research Emerging Growth Invitational 2022 Conference on February 24.

    On February 08, 2022, SLRX announced its CEO’s virtual presence at the 2022 BIO CEO & Investor Conference held on February 14-17. On January 13, 2022, SLRX informed the press about its entry into a definitive contract with DeuteRx, LLC for the acquisition of a small molecule targeted protein degradation platform or SP-3164. On December 29, 2021, SLRX reported the achievement of a dosing milestone in seclidemstat Phase 1/2 trials. The company assessed its efficacy against Ewing sarcoma and FET-rearranged sarcomas and advanced to the second lead-in safety unit.

    SLRX: Key Financials

    On November 04, 2021, SLRX released its unaudited financial report for the third quarter of fiscal 2021 ended September 30, 2021. Some of the key updates are as follows.

    Revenue

    No revenue was recorded by the company for Q3 2021, while a grant revenue of $1.37 million was reported during the same period of 2020.

    EPS

    Net loss per share basic and diluted in the third quarter of 2021 was $3.7 million, or $0.08 compared to $1.7 million, or $0.10 in the corresponding quarter of 2020. The company experienced a substantial incline in its earnings per share over the year.

    Conclusion

    SLRX stock price dipped 74% in the last year as the restrictions were imposed globally during the pandemic. The company’s stock rebounded in aftermarket trading as it is gearing for the fourth quarter financial statement release. The revenue guidance provided by the company for the quarter is $325 thousand against -$0.08 EPS.

  • Salaruis Pharmaceuticals Inc. (SLRX) stock’s Bullish Momentum Escalated After Hours. Why?

    Salaruis Pharmaceuticals Inc. (SLRX) stock’s Bullish Momentum Escalated After Hours. Why?

    On February 25, Salaruis Pharmaceuticals Inc. (SLRX) stock’s bullish momentum escalated in the after-hours as it added a further 10.03%. It seems investors are buying the stock due to its price’s downfall recently.

    During the regular session, the stock added 3.33% at its closing price of $0.3999 per share. The stock traded at a mild volume of just 18% of its 65-day average at 67.08K shares during the regular trading session. Still being quite near the recent 52-week low of $0.3507, SLRX stock continued gaining in the after-hours but with increased momentum. The stock reached a value of $0.4400 in the after-hours on Friday as it added a further $0.04 or 10.03%.

    The clinical-stage oncology company, Salaruis Pharmaceuticals Inc. has a market capitalization of $18.08 million. Currently, the company has 45.21 million shares outstanding in the market.

    What is Happening with SLRX?

    As most of the stock plunged down to new lows in recent days, SLRX also reached its 52-week low of $0.3510 on Thursday. The stock closed the session just above the new low at $0.3870. Thus, leading the way for investors to buy the stock in order to take advantage of the low price. Therefore, the stock entered an uptrend in the following sessions on Friday. While the regular trading saw a mild volume with a normal gain, things changed in the after-hours session as it gained momentum.

    The overall analysis of the stock movement shows a loss of 6.91% in the past five days alone. While the stock stands at a year-to-date loss of 19.31% it subtracted a value of 77.78% last year.

    Company News

    On February 24, the company’s CEO, David Arthur presented at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference.

    On February 22, the company filed a report on Form S-8, Securities to be offered to employees in employee benefit plans.

    Before that, SLRX’s CEO also presented at the 2022 BIO CEO & Investor Conference which took place from February 14 to 17, 2022.

    SLRX’s Financial Highlights

    In the third quarter of 2021, the company had a net loss of $3.7 million, against $1.7 mullion in the year-ago period. Resultantly, the net loss per basic and diluted share was $0.08 and $0.10 in Q3 of 2021 and 2020, respectively.

    Furthermore, as of September 30, 2021, the total working capital of the company was $33.6 million.

  • Dosing Milestone in Phase ½ Sarcoma Trial: Salarius Pharmaceuticals, Inc. (SLRX) Bullish After Hours

    Dosing Milestone in Phase ½ Sarcoma Trial: Salarius Pharmaceuticals, Inc. (SLRX) Bullish After Hours

    Salarius Pharmaceuticals, Inc. (SLRX) stock rebounded in the after-hours on the news of dosing milestone achievement in its ongoing trial. On December 29, the company announced achieving doing milestone in its Phase ½ Sarcoma Trial.

    During the regular session, the stock was in the red with a loss of 6.19% at its closing price of $0.4925. Following the news, the stock became bullish in the after-hours, reaching $0.5200 with a 5.58% gain.

    Currently, SLRX’s 44.78 million outstanding shares trade at a market capitalization of $23.51 million.

    Phase ½ Sarcoma Trial

    The company is conducting Phase ½ Sarcoma clinical trial for the evaluation of seclidemstat. Moreover, scelidemstat is under evaluation as a treatment for Ewing sarcoma and other FET-rearranged sarcomas. As per the recent announcement, the trial’s Ewing sarcoma patient arm has reached its second lead-in safety cohort. Moreover, this cohort would be treating the patients with seclidemstat 900 mg BID in combination with topotecan and cyclophosphamide.

    Seclidemstat is a reversible inhibitor of the LSD1 enzyme that is known to have an important role in the development as well as the progression of some cancers.

    In addition, the company expects potential data readouts from the trial in 2022, as enrollment continues in all patient groups. Currently, patient enrollment is happening across the U.S. at 13 clinical trial sites.

    SLRX’s Recent Developments

    Recently, the company participated in two conferences in the month of December.

    Firstly, SLRX’s CEO David Arthur presented at the Life Science Investor Forum which took place on December 16, 2021. Mr. Arthur shared an overview of the company’s achievements and upcoming milestones at the conference. Moreover, he also discussed the ongoing Phase ½ Sarcoma clinical trial of scelidemstat.

    Secondly, Mr. Arthur along with other members of SLRX participated in the Benchmark Company Discovery One-On-One Investor Conference. Moreover, this conference was held virtually on Thursday, December 2, 2021. Mr. Arthur and the management team hosted one-on-one meetings with the registered investors at the conference.

    SLRX’s Financials

    On November 04, the company declared its financial results for the third quarter of 2021.

    SLRX incurred a net loss per basic and diluted share of $0.08 (total net loss $3.7 million) in the third quarter of 2021. This compares to $0.10 (total net loss of $1.7 million) in the third quarter of 2020.

    Moreover, the company ended the third quarter with a working capital of $33.6 million on September 30, 2021.

  • Biotech Roundup &The delivery of the Pfizer’s vaccine to U.S. – starts Today

    Biotech Roundup &The delivery of the Pfizer’s vaccine to U.S. – starts Today

    This weekend, the U.S. government is packaging millions of doses of the coronavirus vaccine from Pfizer and BioNTech for distribution to places around the country, a mammoth logistics task in favor of what could be the most difficult immunization campaign in history.

    In delivering the vaccine, which is delicate and needs careful care, FedEx and UPS would play key roles. At the terminal, shipments can gain preferential entry. If a plane arrives to land with vaccinations, other passenger flights may have to loop around to wait for their chance.

    The arrival of the first vaccines comes as the virus continues to rage through the USA, with more than 207,000 new cases identified on Saturday by authorities. That took the number to more than 16 million, the most in the world by far. For the first time on Wednesday, more than 3,000 deaths were reported, and the country’s number is nearing 300,000.

    vTv Therapeutics Inc. (NASDAQ:VTVT) shares were trading up 41.55% at $3.10 at the time of writing on Friday. The firm on November 25, 2020 announced common stock purchase agreement for up to $47 million with Lincoln Park Capital.

    vTv Therapeutics Inc. (NASDAQ:VTVT) share price went from a low point around $1.44 to briefly over $4.23 in past 52 weeks, though shares have since pulled back to $3.10. VTVT market cap has remained high, hitting $161.79M at the time of writing, giving it price-to-sales ratio of more than 7350.

    If we look at the recent analyst rating VTVT, H.C. Wainwright initiated coverage on VTVT shares with a Buy rating.

    aTyr Pharma Inc. (LIFE) last closed at $4.64, in a 52-week range of $2.13 to $7.62. The company on November 13, 2020 released third quarter results and provided a corporate update.

    ADiTx Therapeutics Inc. (ADTX) stock soar by 3.77% to $2.48. The firm reported on December 8, 2020, that it will present at the 13th annual LD Micro main event conference on Tuesday, December 15, 2020 at 11:00 AM EST / 8:00 AM PST.

    9 Meters Biopharma Inc. (NASDAQ:NMTR) Shares headed falling, lower as much as -11.75%.

    Iterum Therapeutics plc (NASDAQ:ITRM) rose 11.72% after gaining more than $0.1 on Friday. The biotechnology firm declared on December 7,2020, filing of US patent application based on favorable written opinion of the International Search Authority.

    Vaxart Inc. (VXRT) last closed at $7.44, in a 52-week range of $0.28 to $17.49.

    Catabasis Pharmaceuticals Inc. (CATB) stock soar by 14.51% to $2.21. The most recent rating by Wedbush, on November 02, 2020, is at a Neutral.

    Advaxis Inc. (NASDAQ:ADXS) Shares headed rising, higher as much as 3.56%. The company on November 27, 2020 reported the closing of $9.2 million public offering. The most recent rating by Barclays, on August 03, 2016, is at an Overweight.

    Xeris Pharmaceuticals Inc. (NASDAQ:XERS) rose 11.74% after gaining more than $0.48 on Friday following an announcement from the company that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive Opinion for Ogluo™ (glucagon).

    Novavax Inc. (NVAX) last closed at $124.88, in a 52-week range of $3.65 to $189.40. The firm on December 9, 2020, declared the appointment of Margaret G. McGlynn, R. Ph. to its board as an independent director. Analysts have a consensus price target of $186.20.

    Corbus Pharmaceuticals Holdings Inc. (CRBP) stock soar by 1.52% to $1.34. The most recent rating by ROTH Capital, on September 08, 2020, is at a Neutral.

    Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares headed falling, lower as much as -1.23%. The most recent rating by Mizuho, on April 22, 2020, is at a Neutral.

    Novan Inc. (NASDAQ:NOVN) rose 1.10% after gaining more than $0.01 on Friday.

    Nabriva Therapeutics plc (NBRV) last closed at $2.44, in a 52-week range of $3.26 to $18.29. The company recently announced pricing of $15 million public offering.

    Salarius Pharmaceuticals Inc. (SLRX) stock drop by -31.34% to $0.92 after declaring that it has entered into agreements with several institutional and accredited investors to exercise of warrants for $3.5 million of gross proceeds to be used for ongoing development of Seclidemstat. The most recent rating by Ladenburg Thalmann, on April 27, 2020, is at a Buy.